Welcome to our dedicated page for Boston Scientific news (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scientific stock.
Boston Scientific Corp. (BSX) is a leading global medical technology company that specializes in the development, manufacture, and marketing of medical devices for interventional medical procedures. The company's operations are divided into two main segments: MedSurg and Cardiovascular. With a focus on less invasive medical devices, Boston Scientific's products are designed for insertion into the human body through small openings or cuts, making them essential in various medical fields.
The company's product portfolio includes devices for angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and the treatment of incontinence. Boston Scientific markets its innovative solutions to healthcare professionals and institutions worldwide, with nearly half of its total sales coming from foreign markets.
Recently, the company made headlines with a successful public offering of €2,000,000,000 in aggregate principal amount of notes. These funds are intended to finance the acquisition of Axonics, Inc. and to repay existing debt, showcasing Boston Scientific's strategic financial management.
Significant advancements include the FDA approval for the AGENT™ Drug-Coated Balloon (DCB), aimed at treating coronary in-stent restenosis in patients with coronary artery disease. This novel device marks the first drug-coated coronary balloon available in the U.S., providing a dedicated treatment option for this challenging condition.
Boston Scientific is also expanding its strategic cooperation with Scivita Medical Technology Co., Ltd., focusing on the development and global distribution of endoscopic devices. This collaboration underscores the company's commitment to advancing medical technologies that enhance patient care.
On the financial front, Boston Scientific reported net sales of $3.856 billion for the first quarter of 2024, a 13.8% increase from the previous year. The company's diverse portfolio and robust pipeline, including the recent launch of the FARAPULSE™ Pulsed Field Ablation System, have been key drivers of this growth.
Looking ahead, Boston Scientific is actively involved in clinical trials such as the NAVIGATE-PF study for the FARAWAVE™ Nav Pulsed Field Ablation Catheter and the MODULAR ATP trial for the mCRM™ System. These trials aim to further improve patient outcomes and expand the company's product offerings.
As a global leader in medical technology, Boston Scientific remains committed to transforming lives through innovative solutions that address unmet patient needs and reduce healthcare costs. Stay updated with the latest developments by visiting their website and connecting on LinkedIn and X, formerly Twitter.
Boston Scientific Corporation (BSX) announced a partial offer to acquire up to 65% of Acotec Scientific Holdings Limited for HK$20 per share, totaling approximately US$523 million. Acotec specializes in innovative medical solutions, generating RMB 339 million in sales for the 12 months ending June 30, 2022, reflecting a 25% year-over-year growth. The acquisition aims to enhance Boston Scientific's presence in China and commercialize Acotec's products globally. While the expected impact on adjusted earnings per share is immaterial in 2023, the transaction's completion is subject to shareholder approval.
Boston Scientific has announced a definitive agreement to acquire Apollo Endosurgery for $10 per share, valuing the deal at approximately $615 million. This acquisition aims to enhance Boston Scientific's endoluminal surgery portfolio and expand its presence in the endobariatric market, a growing sector for weight management solutions. Apollo is projected to generate net sales of around $76 million in 2022, driven by its innovative endoscopic suturing systems. The transaction is expected to close in the first half of 2023, with minimal impact on adjusted earnings per share in 2023 but accretive thereafter.
Boston Scientific Corporation (NYSE:BSX) announced the initial results from the ACURATE neo2 Post Market Clinical Follow-up study. Key findings include a high procedural success rate of 98.4%, low mortality rates of 0.8% at 30 days, and minimal paravalvular leaks. The study involved 250 patients and highlighted significant safety and effectiveness of the ACURATE neo2 Aortic Valve System. Notable outcomes included a 6.5% new pacemaker implantation rate and a 0% incidence of disabling stroke. These findings bolster confidence in the valve's design improvements.
Boston Scientific (NYSE: BSX) will participate in two key investor conferences. On November 15, 2022, executives Dan Brennan and Lauren Tengler will engage in a 30-minute Q&A at the 2022 Stifel Healthcare Conference, starting at 8:00 a.m. EST. Following this, on November 30, 2022, Jeff Mirviss, Catherine Jennings, Dr. Michael Jaff, and Lauren Tengler will hold a 45-minute Q&A at the 5th Annual Evercore ISI HealthCONx Conference, also at 8:00 a.m. EST. Live webcasts for both events will be available at investors.bostonscientific.com.
Boston Scientific reported third-quarter 2022 net sales of $3.170 billion, an 8.1% increase year-over-year. GAAP net income was $174 million or $0.12 per share, down from $405 million or $0.28 per share the previous year. Adjusted EPS rose slightly to $0.43 from $0.41. Key growth segments included MedSurg and Cardiovascular, with notable expansions in Emerging Markets at 28.1%. The company is revising its full-year outlook, expecting 6.5% growth and EPS between $0.57 and $0.63.
Boston Scientific Corporation (NYSE: BSX) has scheduled a conference call for October 26, 2022, at 8:00 a.m. EDT to discuss financial results and business highlights for Q3 2022, which ended on September 30. The call will be led by CEO Mike Mahoney and CFO Dan Brennan. A press release with the financial results will be issued prior to the call. Investors can access the live webcast and replay on the company’s investor relations website.
Boston Scientific Corporation (BSX) presented results from the PROTECTED TAVR trial at TCT 2022, evaluating the SENTINEL Cerebral Protection System. The trial aimed to assess the reduction of strokes in TAVR patients. While the primary endpoint was not met, a non-significant trend showed a 21% relative risk reduction in all strokes (2.3% with SENTINEL vs. 2.9% without). Notably, there was a significant 60% reduction in disabling strokes (0.5% with SENTINEL vs. 1.3% without, P=0.02). The study involved 3,000 patients across over 50 sites, emphasizing the SENTINEL device's potential benefits in stroke prevention.
Boston Scientific (NYSE: BSX) has received FDA approval to expand the labeling for its WATCHMAN FLX Left Atrial Appendage Closure Device. The update allows for a 45-day dual anti-platelet therapy (DAPT) option as an alternative to the existing oral anticoagulation (OAC) regimen for patients with non-valvular atrial fibrillation (NVAF). This change provides physicians with more treatment flexibility based on patient needs. Clinical data, including analyses of over 8,300 patients, supports the safety and efficacy of the DAPT regimen. The device demonstrated significant advantages in clinical trials, including higher rates of complete occlusion compared to competitors.
Boston Scientific Corporation (NYSE: BSX) will participate in two investor events in September 2022. On September 7, CEO Mike Mahoney and VP Lauren Tengler will engage in a fireside chat at the Wells Fargo Healthcare Conference at 3:10 p.m. EDT. On September 18, the company will host an investor event at the 34th Transcatheter Cardiovascular Therapeutics meeting from 9:00 a.m. to 10:00 a.m. EDT. Key executives will provide a business update. Webcasts of both events will be available online.
Boston Scientific Corporation (NYSE: BSX) announced the acquisition of Obsidio, Inc. on August 15, 2022. The acquisition incorporates Obsidio's Gel Embolic Material (GEM™) technology, recently cleared by the FDA, into Boston Scientific's interventional oncology and embolization portfolio. GEM technology is designed for efficient embolization procedures, offering advantages over current embolics by providing immediate obstruction of blood flow. The transaction is expected to have an immaterial impact on Boston Scientific's earnings in 2022.
FAQ
What is the current stock price of Boston Scientific (BSX)?
What is the market cap of Boston Scientific (BSX)?
What does Boston Scientific Corp. specialize in?
What are the main segments of Boston Scientific?
What recent financial achievement has Boston Scientific announced?
What is the AGENT™ Drug-Coated Balloon (DCB)?
What is the focus of Boston Scientific’s latest clinical trials?
How has Boston Scientific performed financially in 2024?
What are some key products manufactured by Boston Scientific?
How much of Boston Scientific’s sales come from international markets?
Who are Boston Scientific’s customers?
What is Boston Scientific's vision for the future?
